Clinical Trials Logo

Chemotherapy-Induced Neutropenia clinical trials

View clinical trials related to Chemotherapy-Induced Neutropenia.

Filter by:

NCT ID: NCT02251977 Completed - Colorectal Cancer Clinical Trials

Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer

Start date: September 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the efficacy of monosialotetrahexosylganglioside (GM1) for preventing oxaliplatin induced neurotoxicity in colorectal cancer patients who received oxaliplatin-based adjuvant chemotherapy.

NCT ID: NCT02156388 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This study is designed to access the safety, tolerance and Pharmacokinetic/Pharmacodynamic(PK/PD) of single subcutaneous(SC) injection of GW003 in patients with metastatic tumors.

NCT ID: NCT02104830 Active, not recruiting - Clinical trials for Chemotherapy-induced Neutropenia

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients

Start date: September 2013
Phase: Phase 3
Study type: Interventional

BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia®) at a dose of 6 or 7,5 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy. The study also includes the following determination of pharmacokinetic parameters after repeated administration of the study drug.

NCT ID: NCT01923545 Completed - Clinical trials for Chemotherapy Induced Neutropenia

Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

PEG-G-CSF
Start date: July 2010
Phase: Phase 2
Study type: Interventional

This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.

NCT ID: NCT01674855 Completed - Clinical trials for Chemotherapy Induced Neutropenia

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

PEG-G-CSF
Start date: February 2012
Phase: Phase 3
Study type: Interventional

This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily G-CSF in chemotherapy-induced neutropenia.

NCT ID: NCT01569087 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients

Start date: May 2012
Phase: Phase 2
Study type: Interventional

BCD-017-2 is an open-label randomized phase II clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia®) at a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy.

NCT ID: NCT01516736 Completed - Breast Cancer Clinical Trials

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

PROTECT2
Start date: March 2012
Phase: Phase 3
Study type: Interventional

The study will assess the efficacy of LA-EP2006 compared to Peg-Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.

NCT ID: NCT01328938 Completed - Clinical trials for Chemotherapy Induced Neutropenia

GCPGC in Chemotherapy-induced Neutropenia

Start date: October 2010
Phase: Phase 2/Phase 3
Study type: Interventional

This study is adaptive design and it consists of stage I and stage II. Stage I is multi-center, parallel-group, single-blind, phase II study to determine the adequate dose of GCPGC in chemotherapy-induced neutropenia. 2 Different doses of GCPGC will be investigated in a total of 60 Breast cancer patients who are receiving chemotherapy. Stage II is multi-center, parallel-group, double-blind,phase III study to evaluate the efficacy and safety of once per cycle GCPGC in chemotherapy-induced neutropenia compared to Neulasta (pegfilgrastim). A total of 120 patients receiving chemotherapy will participate into this phase.

NCT ID: NCT01126190 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

NEUGR-003
Start date: June 30, 2010
Phase: Phase 3
Study type: Interventional

Determination of the effect of neugranin on the duration and severity of severe neutropenia in participants receiving doxorubicin in combination with docetaxel.

NCT ID: NCT00837265 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

NEUGR-002
Start date: August 21, 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Determination of the effect of balugrastim on the duration and severity of severe neutropenia.